Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer

ABSTRACT: The purpose of this study was to characterise the effects of trastuzumab and pertuzumab, either as single agents or as combination therapy on gene and protein expression in human ovarian cancer in vivo. Illumina BeadChips were used to profile the transcriptome after four days treatment of SKOV3 tumor xenografts. Although genes involved with HER2, MAP-kinase and p53 signaling pathways were commonly induced by all treatments, a greater number and variety of genes were differentially expressed by the complementary combination therapies compared to either drug on its own. The protein level of the CDK-inhibitors p21 and p27 were increased in response to both agents alone and further by the combination; pERK signaling was inhibited by all treatments; but only pertuzumab alone inhibited pAkt sign

ORGANISM(S): Homo sapiens

SUBMITTER: Sims AH 

PROVIDER: S-ECPF-GEOD-31432 | biostudies-other | 2012 May

REPOSITORIES: biostudies-other